Swedish Orphan Biovitrum AB (publ) Q2 2021 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Christopher Winston Uhde - SEB, Research Division - Analyst : Nice results. So my first question is related to this consumption improvement. So to what extent is this due to lockdown relief? And to what extent is it potentially from a different approach by patients or prescribers to the target trough. And my second question is I guess for now, let's say, the China market access team, you have one in place ahead of the potential approvals you've got there because I guess you have roughly a year or so after approval to get on the reimbursement list, right? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. JULY 21, 2021 / 11:00AM, SOBIV.ST - Q2 2021 Swedish Orphan Biovitrum AB (publ) Earnings Call

Question: Rajan Sharma - Deutsche Bank AG, Research Division - Analyst : Thanks for the question. First one, if we could just go back to RSV revenues and just thinking ahead into 2022. Is there a risk of lower RSV revenues if nirsevimab cannibalizes Synagis before broader volumes kick in, in 2023? And then second question, just on the cost outlook for the second half of this year. How should we think about that given that you're already at the top end of the range for full year EBITA margins?

Question: Christopher Winston Uhde - SEB, Research Division - Analyst : So a question on pegcetacoplan in IgA nephropathy. I wondered why are you and Apellis going for this indication, given the iptacopan data. And I wondered, are you held back by the route of administration or the infusion reactions? Or is it something else on efficacy?